GlassScriptPhysician profile
Hansol Haldeman
NPI 1710757984
$5,412.40
in general payments reported to CMS, 2019-2025
30 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,529 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,532 · Travel and Lodging: $1,781 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,532.07 |
| Travel and Lodging | $1,781.33 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $2,230.83 | 2024 | Illuccix |
| Janssen Biotech, INC. | $748.72 | 2024-2025 | Erleada, Rybrevant, Akeega |
| Myriad Genetic Laboratories, INC. | $260.06 | 2024-2025 | Prolaris |
| Alexion Pharmaceuticals, INC. | $229.39 | 2025 | Ultomiris |
| Teleflex LLC | $207.35 | 2024-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $201.61 | 2024-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $178.15 | 2024-2025 | Orgovyx, Gemtesa |
| Angiodynamics, INC. | $154.21 | 2025 | Nanoknife |
| Emd Serono, INC. | $145.91 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.24 | 2025 | |
| Amgen INC. | $128.77 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2024 | Caplyta |
| Olympus America INC. | $121.20 | 2024-2025 | Itind System |
| Novartis Pharmaceuticals Corporation | $96.46 | 2024-2025 | |
| Abbvie INC. | $47.40 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $42.78 | 2024-2025 | |
| Tolmar, INC. | $37.83 | 2025 | Jatenzo, Eligard |
| Blue Earth Diagnostics | $37.61 | 2025 | Posluma |
| Dendreon Pharmaceuticals LLC | $34.11 | 2025 | Provenge |
| Ferring Pharmaceuticals INC. | $33.52 | 2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $32.83 | 2025 | |
| Lundbeck LLC | $27.43 | 2024 | Abilify Asimtufii |
| Laborie Medical Technologies Corp. | $26.73 | 2025 | |
| Endo USA, INC. | $24.41 | 2025 | Xiaflex |
| Tris Pharma INC | $22.49 | 2024 | Dyanavel Xr |
| Biogen, INC. | $20.02 | 2024 | |
| Boston Scientific Corporation | $17.77 | 2025 | Moses |
| Procept Biorobotics Corporation | $15.66 | 2025 | |
| Azurity Pharmaceuticals, INC. | $14.45 | 2024 | Horizant |
| Pfizer INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hansol Haldeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.